According to the statements made by Moderna, the COVID-19 vaccine developed by the company was 94.5 percent effective against the virus. The vaccine has been tested in two doses on 30 thousand people so far.
After the announcement that the COVID-19 vaccine developed by Pfizer with BioNTech in the past weeks was 90 percent effective against the virus, a good news came from the US pharmaceutical company Moderna.
According to the statements made by Moderna Inc., the coronavirus vaccine developed by the company was 94.5 percent effective in a two-dose vaccination study conducted with 30 thousand people. Moderna CEO Stephane Bancel said, “These (the vaccines developed by BioNTech and Moderna) are two excellent vaccines that will help many people in the US and the world.”
Moderna’s coronavirus vaccine is easier to hide than BioNTech’s
Stating that it is too early to compare the vaccine they developed with the vaccine developed by Pfizer and BioNTech; On the other hand, he stated that their vaccines have a significant advantage over BioNTech’s vaccine; storage.
While the coronavirus vaccine developed by BioNTech has to be protected at -70 degrees in dry ice and special storage systems; It is stated that the vaccine developed by Moderna can be stored at standard refrigerator temperatures (2-8 degrees) for up to a month.
Speaking about the supply status of the vaccine, Bancel said that everything could return to normal in the summer of 2021 and that everyone who wants vaccines in the US will reach a safe and effective vaccine until Memorial Day (on the last Monday of May).
The most critical point about the vaccine developed by Moderna is that it has only been tested in adult individuals so far. Moderna plans to test the vaccine for young people as soon as possible, and Bancel says he hopes young people may also wear it in July or August.
“September 2021 would be normal to return to school.” “People can go shopping, take their belongings, backpacks and go back to school without a mask,” said Moderna’s CEO. And they can go back to the normal life we all know. ” used the expressions.
Moderna and Pfizer plan to apply for an Emergency Use Authorization (EUA) in late November in order to launch the vaccine they developed. Because the examinations of the US Food and Drug Administration (FDA) for vaccines may take weeks.
“We will probably be able to get both vaccines approved by the FDA under the EUA in December,” said Bancel. used the expressions. Moderna stated that they plan to produce 100 million doses of vaccine by the end of the first quarter of 2021 and to vaccinate 50 million people with two doses with these vaccines.